Literature DB >> 30591345

Rubiscolins are naturally occurring G protein-biased delta opioid receptor peptides.

Robert J Cassell1, Kendall L Mores1, Breanna L Zerfas1, Amr H Mahmoud1, Markus A Lill2, Darci J Trader2, Richard M van Rijn3.   

Abstract

The impact that β-arrestin proteins have on G protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin. These findings have led to the development of biased opioid small molecule agonists that do not recruit β-arrestin, activating only the canonical G protein pathway. Similar G protein-biased small molecule opioids have been found to occur in nature, particularly within kratom, and opioids within salvia have served as a template for the synthesis of other G protein-biased opioids. Here, we present the first report of naturally occurring peptides that selectively activate G protein signaling pathways at δ opioid receptors, but with minimal β-arrestin recruitment. Specifically, we find that rubiscolin peptides, which are produced as cleavage products of the plant protein rubisco, bind to and activate G protein signaling at δ opioid receptors. However, unlike the naturally occurring δ opioid peptides leu-enkephalin and deltorphin II, the rubiscolin peptides only very weakly recruit β-arrestin 2 and have undetectable recruitment of β-arrestin 1 at the δ opioid receptor.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Beta-arrestin; Biased signaling; Delta opioid receptor; G protein-coupled receptor; Natural products; Rubisco

Mesh:

Substances:

Year:  2018        PMID: 30591345      PMCID: PMC6421079          DOI: 10.1016/j.euroneuro.2018.12.013

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  14 in total

1.  Selection of DNA-Encoded Libraries to Protein Targets within and on Living Cells.

Authors:  Bo Cai; Dongwook Kim; Saeed Akhand; Yixing Sun; Robert J Cassell; Aktan Alpsoy; Emily C Dykhuizen; Richard M Van Rijn; Michael K Wendt; Casey J Krusemark
Journal:  J Am Chem Soc       Date:  2019-10-22       Impact factor: 15.419

Review 2.  Neuropeptide PEN and Its Receptor GPR83: Distribution, Signaling, and Regulation.

Authors:  Seshat M Mack; Ivone Gomes; Lakshmi A Devi
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

3.  Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II.

Authors:  Richard M Van Rijn; Mariana Spetea
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

4.  Modulating β-arrestin 2 recruitment at the δ- and μ-opioid receptors using peptidomimetic ligands.

Authors:  Krishna K Sharma; Robert J Cassell; Yazan J Meqbil; Hongyu Su; Arryn T Blaine; Benjamin R Cummins; Kendall L Mores; David K Johnson; Richard M van Rijn; Ryan A Altman
Journal:  RSC Med Chem       Date:  2021-08-16

Review 5.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21

6.  Isolation and Pharmacological Characterization of Six Opioidergic Picralima nitida Alkaloids.

Authors:  Simone M Creed; Anna M Gutridge; Malaika D Argade; Madeline R Hennessy; J Brent Friesen; Guido F Pauli; Richard M van Rijn; Andrew P Riley
Journal:  J Nat Prod       Date:  2020-12-16       Impact factor: 4.050

7.  A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.

Authors:  Soumen Chakraborty; Jeffrey F DiBerto; Abdelfattah Faouzi; Sarah M Bernhard; Anna M Gutridge; Steven Ramsey; Yuchen Zhou; Davide Provasi; Nitin Nuthikattu; Rahul Jilakara; Melissa N F Nelson; Wesley B Asher; Shainnel O Eans; Lisa L Wilson; Satyanarayana M Chintala; Marta Filizola; Richard M van Rijn; Elyssa B Margolis; Bryan L Roth; Jay P McLaughlin; Tao Che; Dalibor Sames; Jonathan A Javitch; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-09-10       Impact factor: 8.039

8.  G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder.

Authors:  Anna M Gutridge; Meridith T Robins; Robert J Cassell; Rajendra Uprety; Kendall L Mores; Mee Jung Ko; Gavril W Pasternak; Susruta Majumdar; Richard M van Rijn
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

9.  The Meta-Position of Phe4 in Leu-Enkephalin Regulates Potency, Selectivity, Functional Activity, and Signaling Bias at the Delta and Mu Opioid Receptors.

Authors:  Robert J Cassell; Krishna K Sharma; Hongyu Su; Benjamin R Cummins; Haoyue Cui; Kendall L Mores; Arryn T Blaine; Ryan A Altman; Richard M van Rijn
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

10.  Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities.

Authors:  Yazan J Meqbil; Hongyu Su; Robert J Cassell; Kendall L Mores; Anna M Gutridge; Benjamin R Cummins; Lan Chen; Richard M van Rijn
Journal:  Molecules       Date:  2021-11-29       Impact factor: 4.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.